3 unchanged sentences
LISATA THERAPEUTICS, INC.
−Removed: November 10, 2022 By:
+Added: May 9, 2023 By:
Chief Executive Officer
3 unchanged sentences
Exhibit Index
−Removed: Agreement and Plan of Merger and Reorganization, dated April 26, 2022, among Caladrius Biosciences, Inc., CS Cedar Merger Sub, Inc., and Cend Therapeutics, Inc.
−Removed: (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: Form of Support Agreement, by and between Caladrius Biosciences, Inc.
−Removed: and certain securityholders of Cend Therapeutics, Inc.
−Removed: (filed as Exhibit 2.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: Form of Support Agreement, by and between Cend Therapeutics, Inc.
−Removed: and certain securityholders of Caladrius Biosciences, Inc.
−Removed: (filed as Exhibit 2.3 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: Form of Lock-Up Agreement, by and between Caladrius Biosciences, Inc.
−Removed: and certain securityholders of Caladrius Biosciences, Inc.
−Removed: and Cend Therapeutics, Inc.
−Removed: (filed as Exhibit 2.4 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated September 14, 2022 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).
−Removed: Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation, dated September 15, 2022 (filed as Exhibit 3.2 of the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).
−Removed: Series D Preferred Stock Purchase Agreement, dated April 26, 2022, among Caladrius Biosciences, Inc.
−Removed: and Cend Therapeutics, Inc.
−Removed: (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: Collaboration Agreement, dated April 26, 2022, between Caladrius Biosciences, Inc.
−Removed: and Cend Therapeutics, Inc.
−Removed: (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).
−Removed: # Employment Agreement, dated as of September 15, 2022, by and between the Company and David Slack (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).
−Removed: # Form of Indemnification Agreement between the Company and each of its directors and officers (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).
−Removed: # Cend 2016 Equity Incentive Plan, including all amendments thereto (filed as Exhibit 99.1 to the Company's Registration Statement on Form S-8, filed with the SEC on October 17, 2022).
* Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
11 unchanged sentences
** Furnished herewith.
−Removed: # Management contract or compensatory plans or arrangements.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.